Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ampyra Trial Failure Is Not All Bad News For Acorda

This article was originally published in The Pink Sheet Daily

Executive Summary

Lower dose of Acorda’s MS drug Ampyra fails to meet primary endpoint in new study, reassuring investors on the IP front. But the higher, approved dose also missed the mark, which raises questions about a negative commercial impact.

Advertisement

Related Content

“The Pink Sheet” DAILY’s Most Popular Stories Last Week
Ampyra Seizure Warnings Strengthened Followed Continued Reports
The Long Road To Approval: Acorda Experience With Ampyra Shows Success Of Novel Analysis Plan
Everything Old Is New Again: History Of Compounding Shaped Ampyra REMS
Acorda's Novel Primary Endpoint For Ampyra Was Made Possible By A Supporting Scaffolding Of Secondary Analyses

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074503

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel